神经节苷脂联合普拉克索治疗血管性帕金森临床观察

Clinical observation of ganglioside combined with pramipexole on vascular Parkinson's

目的观察神经节苷脂联合普拉克索治疗血管性帕金森的临床疗效。方法 94例血管性帕金森患者随机分为对照组及观察组,每组47例。两组基础治疗相同,观察组加用普拉克索0.25 mg/次,3次/d,神经节苷脂40 mg,1次/d;对照组加用美多巴,开始剂量每次1/4片,每日3次,逐渐加量,每日最多不超过5片。治疗12周后,比较两组治疗前后UPDRS评分和总有效率。结果观察组的UPDRS评分与对照组比较差异有统计学意义(P<0.05),总有效率也明显优于对照组(P<0.05)。结论神经节苷脂联合普拉克索可有效治疗血管帕金森病。

Objective To observe the clinical efficacy of ganglioside combined with pramipexole on vascular Parkinsonism. Methods 94 cases of vascular parkinsonism patients were randomly divided into control group and ob-servation group ,47 cases in each group. Observation group was given pramipexole 0.25 mg, three times a day, ganglio-side 40 mg ＋ 250 mL 0. 9% saline injection, once daily. Control group was given madopa, starting dose 1/4 tablets, 3 times daily, the volume was gradually increased （not more than 5 tablets daily）. After 12 weeks, the UPDRS score and total efficiency of the two groups were compared. Results There were significant differences in the UPDRS score and the total efficiency between the two groups （ P 〈 0. 05 ）. Conclusion Ganglioside combined pramipexole is effective to treat vascular parkinsonism.